Wound-Healing Effects of Mesenchymal Stromal Cell Secretome in the Cornea and the Role of Exosomes
-
Published:2023-05-13
Issue:5
Volume:15
Page:1486
-
ISSN:1999-4923
-
Container-title:Pharmaceutics
-
language:en
-
Short-container-title:Pharmaceutics
Author:
An Seungwon1, Anwar Khandaker1, Ashraf Mohammadjavad12, Lee Hyungjo1, Jung Rebecca1, Koganti Raghuram1ORCID, Ghassemi Mahmood1ORCID, Djalilian Ali R.1
Affiliation:
1. Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL 60612, USA 2. Department of Pathology, Shiraz University of Medical Sciences, Shiraz 71348-14336, Iran
Abstract
Mesenchymal stromal/stem cells (MSCs) and their secreted factors have been shown to have immunomodulatory and regenerative effects. In this study, we investigated human bone-marrow-derived MSC secretome (MSC-S) for the treatment of corneal epithelial wounds. Specifically, we evaluated the role of MSC extracellular vesicles (EV)/exosomes in mediating the wound-healing effects of the MSC-S. In vitro studies using human corneal epithelial cells showed that MSC-CM increased cell proliferation in HCEC and HCLE cells, while EV-depleted MSC-CM showed lower cell proliferation in both cell lines compared to the MSC-CM group. In vitro and in vivo experiments revealed that 1X MSC-S consistently promoted wound healing more effectively than 0.5X MSC-S, and MSC-CM promoted wound healing in a dose-dependent manner, while exosome deprivation delayed wound healing. We further evaluated the incubation period of MSC-CM on corneal wound healing and showed that MSC-S collected for 72 h is more effective than MSC-S collected for 48 h. Finally, we evaluated the stability of MSC-S under different storage conditions and found that after one cycle of freeze–thawing, MSC-S is stable at 4 °C for up to 4 weeks. Collectively, we identified the following: (i) MSC-EV/Exo as the active ingredient in MSC-S that mediates the wound-healing effects in the corneal epithelium, providing a measure to optimize its dosing for a potential clinical product; (ii) Treatment with EV/Exo-containing MSC-S resulted in an improved corneal barrier and decreased corneal haze/edema relative to EV/Exo-depleted MSC-S; (iii) The stability of MSC-CM for up to 4 weeks showed that the regular storage condition did not significantly impact its stability and therapeutic functions.
Funder
R01 NEI/NIH UIC Department of Ophthalmology and Physician-Scientist Award Research to Prevent Blindness, and Eversight
Subject
Pharmaceutical Science
Reference90 articles.
1. Mesenchymal stem cell perspective: Cell biology to clinical progress;Pittenger;NPJ Regen. Med.,2019 2. Different populations and sources of human mesenchymal stem cells (msc): A comparison of adult and neonatal tissue-derived msc;Hass;Cell Commun. Signal,2011 3. An, S., Shen, X., Anwar, K., Ashraf, M., Lee, H., Koganti, R., Ghassemi, M., and Djalilian, A.R. (2022). Therapeutic potential of mesenchymal stem cell-secreted factors on delay in corneal wound healing by nitrogen mustard. Int. J. Mol. Sci., 23. 4. Isolation, differentiation, and characterization of mesenchymal stem cells from human bone marrow;Baghaei;Gastroenterol. Hepatol. Bed Bench,2017 5. Vasanthan, J., Gurusamy, N., Rajasingh, S., Sigamani, V., Kirankumar, S., Thomas, E.L., and Rajasingh, J. (2020). Role of human mesenchymal stem cells in regenerative therapy. Cells, 10.
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|